MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer.
Lars D EngstromRuth ArandaLaura WatersKrystal MoyaVickie BowcutLaura VegarDavid TrinhAllan HebbertChristopher R SmithSvitlana KulykJ David LawsonQuanyuan HeLaura D HoverJulio Fernandez-BanetJill HallinDarin VanderpoolDavid M BriereAlice BlajMatthew A MarxJordi Rodon AhnertMichael D OffinKathryn C ArbourMelissa Lynne JohnsonDavid J KwiatkowskiPasi A JanneCandace L HaddoxKyriakos P PapadopoulosJason T HenryKonstantinos LeventakosJames G ChristensenRonald ShazerPeter OlsonPublished in: Cancer discovery (2023)
Previous studies implicated PRMT5 as a synthetic lethal target for MTAP deleted (MTAP del) cancers, however, the pharmacological characterization of small molecule inhibitors that recapitulate the synthetic lethal phenotype have not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selectivity in HCT116 MTAP del compared to HCT116 MTAP WT cells. MRTX1719 demonstrated dose-dependent anti-tumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts, mouse or human hematopoietic cells. MRTX1719 demonstrated marked anti-tumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non-small cell lung cancer, and MPNST from the Phase 1/2 study.